Sarepta Therapeutics slumps after second death in gene therapy trial

Shares of Sarepta Therapeutics SRPT.O slump 45.8% to $19.6, after co discloses second death in gene therapy treatment for a rare form of muscular dystrophy

Shares fall to a more than 9-year low

The first death was reported in March

Liver damage is a known risk with Elevidys and other gene therapies using adeno-associated viral vectors to infuse modified genes

Co says it has suspended shipments of therapy for non-ambulatory patients and informed global health authorities and FDA

Including session's losses, SRPT down 84.1% YTD